Maintaining MOMENTUM in myelofibrosis

被引：0
|
作者：
Kremyanskaya, Marina [1 ,2 ]
Marcellino, Bridget K. [1 ,2 ]
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol Oncol, Dept Med, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 09期
关键词：
AVAILABLE THERAPY; RUXOLITINIB;
D O I：
10.1016/S2352-3026(23)00208-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E697 / E699
页数：3
相关论文
共 50 条
  • [1] Gaining MOMENTUM against anaemic myelofibrosis
    Ikeda, Kazuhiko
    Ueda, Koki
    LANCET, 2023, 401 (10373) : 248 - 249
  • [2] Momelotinib in myelofibrosis
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Labanca, Caterina
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Zimbo, Annamaria
    Fragliasso, Valentina
    Neri, Antonino
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (05) : 521 - 528
  • [3] Fedratinib in myelofibrosis
    Mullally, Ann
    Hood, John
    Harrison, Claire
    Mesa, Ruben
    BLOOD ADVANCES, 2020, 4 (08) : 1792 - 1800
  • [4] COMBINATION THERAPY FOR MYELOFIBROSIS
    Gribkova, I., V
    Oleinik, Yu. A.
    Shalaev, S. A.
    Davydovskaya, M., V
    Kokushkin, K. A.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 64 (02): : 188 - 197
  • [5] Efficacy of ruxolitinib for myelofibrosis
    Santos, Fabio P. S.
    Verstovsek, Srdan
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1465 - 1473
  • [6] Novel therapeutics for myelofibrosis
    Lee, Sung-Eun
    BLOOD RESEARCH, 2023, 58 : 13 - 19
  • [7] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Sliwa, Thamer
    Beham-Schmid, Christine
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Gastl, Guenther
    Geissler, Klaus
    Krauth, Maria
    Krippl, Peter
    Lang, Alois
    Petzer, Andreas
    Woehrer, Stefan
    Woelfler, Albert
    Gisslinger, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
  • [8] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
    Verstovsek, Srdan
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Al-Ali, Haifa Kathrin
    Lavie, David
    Kuykendall, Andrew T.
    Grosicki, Sebastian
    Iurlo, Alessandra
    Goh, Yeow Tee
    Lazaroiu, Mihaela C.
    Egyed, Miklos
    Fox, Maria Laura
    McLornan, Donal
    Perkins, Andrew
    Yoon, Sung -Soo
    Gupta, Vikas
    Kiladjian, Jean -Jacques
    Granacher, Nikki
    Lee, Sung-Eun
    Ocroteala, Luminita
    Passamonti, Francesco
    Harrison, Claire N.
    Klencke, Barbara J.
    Ro, Sunhee
    Donahue, Rafe
    Kawashima, Jun
    Mesa, Ruben
    LANCET, 2023, 401 (10373) : 269 - 280
  • [9] Idiopathic myelofibrosis in internal medicine
    Garcia-Gutierrez, Valentin
    Redondo, Santiago
    Ruedas, Angel
    MEDICINA CLINICA, 2014, 143 (11): : 498 - 501
  • [10] Current Clinical Investigations in Myelofibrosis
    Venugopal, Sangeetha
    Mascarenhas, John
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (02) : 353 - 373
12345